Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Rheumatoid Arthritis in 17 Major Markets
Rheumatoid arthritis (RA) is classified as an autoimmune disease and occurs when the immune system attacks the synovium (membranes surrounding joints). The inflammation resulting from the attack causes thickening of the synovium, which eventually destroys the cartilage and bone within the joint. The tendons and ligaments holding the joint together weaken and stretch, resulting in gradual loss of joint shape and alignment.
Prevalence of RA has been rumoured to be in decline over the past 20-30 years, although there is nothing concrete in the literature to substantiate if this is actually the case.
This report provides the current prevalent population for Rheumatoid Arthritis across 17 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, NL, Denmark, Norway, Greece, Turkey, Brazil, Mexico, Argentina, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Rheumatoid Arthritis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
The following are considered features or comorbid conditions associated with RA:
• Smoking
• Obesity
• Diabetes
• Metabolic syndrome
• Hypertension
• Extra-articular manifestations
• Erosive disease
• Cachexia (muscle wasting)
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in the global Rheumatoid Arthritis market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Rheumatoid Arthritis and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Rheumatoid Arthritis’s prevalent population.
• Identify sub-populations within Rheumatoid Arthritis which require treatment.
• Gain an understanding of the specific markets that have the largest number of Rheumatoid Arthritis patients.
'
Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key Co-morbid Conditions associated with the Disease
• Methodology for Quantification of Patient Numbers
• Top-Line Prevalence for Rheumatoid Arthritis
• Clinical Features of RA Patients
o RA Patients by MHAQ Score
o RA Patients by ACR Functional Class
o Articular Invovlement in RA Patients
o Smoking Status in RA Patients
• Comorbidities and Biomarkers of RA Patients
• RA Patients treated by Rheumatologists
• Abbreviations and Acronyms used in the Report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
List of Figures
• Joint Changes due to inflammation in RA
• Geographic distribution of HLA-B27
List of Tables
• ACR Classification of functional capacity in rheumatoid arthritis
• Prevalence of RA, total
• Prevalence of RA, males
• Prevalence of RA, females
• RA patients by MHAQ Score, total
• RA patients by ACR Functional Class, total
• RA patients by Articular involvement, total
• RA patients by Smoking status, total
• RA patients with Erosive disease, total
• RA patients with Extra-articular manifestations, total
• RA patients with Rheumatoid nodules, total
• RA patients positive for Rheumatoid factor, total
• RA patients positive for anti-CCP, total
• RA patients with Cachexia, total
• RA patients with Diabetes, total
• RA patients with Hypertension, total
• RA patients with AIHA, total
• RA patients managed by rheumatologist, total
• Abbreviations and Acronyms used in the report
• USA Prevalence of Rheumatoid Arthritis by 5-yr age cohort, males (000s)
• USA Prevalence of Rheumatoid Arthritis by 5-yr age cohort, females (000s)
• Canada Prevalence of Rheumatoid Arthritis by 5-yr age cohort, males (000s)
• Canada Prevalence of Rheumatoid Arthritis by 5-yr age cohort, females (000s)
• France Prevalence of Rheumatoid Arthritis by 5-yr age cohort, males (000s)
• France Prevalence of Rheumatoid Arthritis by 5-yr age cohort, females (000s)
• Germany Prevalence of Rheumatoid Arthritis by 5-yr age cohort, males (000s)
• Germany Prevalence of Rheumatoid Arthritis by 5-yr age cohort, females (000s)
• Italy Prevalence of Rheumatoid Arthritis by 5-yr age cohort, males (000s)
• Italy Prevalence of Rheumatoid Arthritis by 5-yr age cohort, females (000s)
• Spain Prevalence of Rheumatoid Arthritis by 5-yr age cohort, males (000s)
• Spain Prevalence of Rheumatoid Arthritis by 5-yr age cohort, females (000s)
• UK Prevalence of Rheumatoid Arthritis by 5-yr age cohort, males (000s)
• UK Prevalence of Rheumatoid Arthritis by 5-yr age cohort, females (000s)
• Netherlands Prevalence of Rheumatoid Arthritis by 5-yr age cohort, males (000s)
• Netherlands Prevalence of Rheumatoid Arthritis by 5-yr age cohort, females (000s)
• Denmark Prevalence of Rheumatoid Arthritis by 5-yr age cohort, males (000s)
• Denmark Prevalence of Rheumatoid Arthritis by 5-yr age cohort, females (000s)
• Norway Prevalence of Rheumatoid Arthritis by 5-yr age cohort, males (000s)
• Norway Prevalence of Rheumatoid Arthritis by 5-yr age cohort, females (000s)
• Greece Prevalence of Rheumatoid Arthritis by 5-yr age cohort, males (000s)
• Greece Prevalence of Rheumatoid Arthritis by 5-yr age cohort, females (000s)
• Turkey Prevalence of Rheumatoid Arthritis by 5-yr age cohort, males (000s)
• Turkey Prevalence of Rheumatoid Arthritis by 5-yr age cohort, females (000s)
• Brazil Prevalence of Rheumatoid Arthritis by 5-yr age cohort, males (000s)
• Brazil Prevalence of Rheumatoid Arthritis by 5-yr age cohort, females (000s)
• Mexico Prevalence of Rheumatoid Arthritis by 5-yr age cohort, males (000s)
• Mexico Prevalence of Rheumatoid Arthritis by 5-yr age cohort, females (000s)
• Argentina Prevalence of Rheumatoid Arthritis by 5-yr age cohort, males (000s)
• Argentina Prevalence of Rheumatoid Arthritis by 5-yr age cohort, females (000s)
• Japan Prevalence of Rheumatoid Arthritis by 5-yr age cohort, males (000s)
• Japan Prevalence of Rheumatoid Arthritis by 5-yr age cohort, females (000s)
• India Prevalence of Rheumatoid Arthritis by 5-yr age cohort, males (000s)
• India Prevalence of Rheumatoid Arthritis by 5-yr age cohort, females (000s)
